Amid rising concern over prescription drug pricing, Senator Chuck Grassley (R-Iowa) has begun an investigation into whether drug makers are exploiting loopholes to widen the market for so-called orphan drugs.

The move comes after accelerating scrutiny of this lucrative corner of the pharmaceutical market. Under the Orphan Drug Act, which was passed in 1983, the Food and Drug Administration began approving medicines to treat rare diseases that affect fewer than 200,000 people. The incentives to fill these unmet medical needs include tax credits and seven years of exclusive marketing rights.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • ODA is racket of PhRMA and politicians who are on sale.
    PhRMA should not feel bad. They are the ones who bought the legislators to benefit from every corner. Since 1983 when the ODA was passed 5,732 drugs have been requested orphan drug status. 3,986 drugs were given the status and 599 have been approved. In recent years most of them are priced in six digits. Whole idea is to make money and fill their pockets. Poor patient is going to die sooner or later. Who cares if that happens. Normal process of living.
    Point is make drugs affordable but not at the expense of patient and their family.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy